脳炎ワクチンの世界市場規模：菌株別、エンドユーザー別、地域範囲別および予測

脳炎ワクチンの市場規模と予測

脳炎ワクチンの市場規模は、2024年に12億6,913万米ドルと評価され、2026年から2032年にかけてCAGR 5.52%で成長し、2032年には18億7,565万米ドルに達すると予測されています。

脳炎ウイルスの罹患による死亡率と罹患率の高さは、多地域間で意識を高め、市場成長を牽引している憂慮すべき要因です。様々な政府による取り組みや簡単な政策、適切な治療補助が市場の成長に寄与しています。世界の脳炎ワクチン市場レポートは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界の脳炎ワクチン市場の定義

脳炎ウイルスは蚊を媒介とするフラビウイルスで、蚊から渡り鳥、ブタ、その他の脊椎動物を宿主として感染します。このウイルスは、脳炎ワクチンを用いて予防することができます。脳炎ウイルスの発生率は一般的に低いですが、場所や季節によって異なります。このウイルスは脳炎ワクチンで予防することができます。脳炎ウイルスに感染した蚊に刺されると、人を通じて感染する可能性があり、農村部の農業地域で最も多く発生しているため、アジア太平洋地域で最も多くの患者が発生しています。

脳炎ワクチンの世界市場概要

脳炎ウイルスによる死亡率の高さから、世界市場は比較的高い成長率で拡大しています。また、子供への予防接種を推奨する政府の取り組みが増加していることも、市場の成長を後押ししています。これらのワクチンの利点に関する認知度向上のためのキャンペーンやプログラムが増加していることなどが、市場にとって好機となっています。これらの要因を総合すると、近い将来、脳炎ワクチンの需要が増加すると予測されます。

目次

第1章 世界の脳炎ワクチン市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 脳炎ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 脳炎ワクチンの世界市場：菌株別

• 概要
• 中山
• 北京
• P-3
• SA1414-2

第6章 脳炎ワクチンの世界市場：エンドユーザー別

• 概要
• 小児
• 成人

第7章 脳炎ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の脳炎ワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Liaoning Chengda
• Valneva
• Tiantan Biological Products
• Sanofi Pasteur
• Chengdu Institute of Biological Products
• GlaxoSmithKline plc
• Lanzhou Institute of Biological Products
• Zhejiang Tianyuan Bio-Pharmaceutical
• Biken

第10章 付録

• 関連調査

Encephalitis Vaccine Market Size And Forecast

Encephalitis Vaccine Market size was valued at USD 1269.13 Million in 2024 and is projected to reach USD 1875.65 Million by 2032, growing at a CAGR of 5.52% from 2026-2032.

The high mortality and morbidity rate caused due to the incidence of encephalitis virus is an alarming factor that is creating awareness among multiple regions and is driving the market growth. The inititives by various government and easy policies and proper treatment aids are contributing to the growth of the market. The Global Encephalitis Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Encephalitis Vaccine Market Definition

Encephalitis virus is a mosquito-borne Flavivirus that can be transmitted from mosquitoes to wading birds, pigs and other vertebrate hosts. This virus can be prevented using Encephalitis vaccines. The incidence rate for the Encephalitis virus is in a general low but can depend on the location and the season. This virus can be prevented using Encephalitis vaccines. As an Encephalitis infected mosquito bite can also be transmitted through humans and most commonly occurs in rural agricultural areas, thus Asia Pacific has witnessed the most number of cases.

Global Encephalitis Vaccine Market Overview

The global market is witnessing expansion at a relatively higher growth rate owing to the high mortality rate caused due to the encephalitis virus. The rise in government initiatives and recommendations to immunize children is also aiding the growth of the market. Factors such as the growing number of campaigns and programs for the improvement in awareness regarding the benefits of these vaccines are acting as an opportunity for the market. These factors, collectively, are projected to increase the demand for Encephalitis Vaccine in the near future.

Global Encephalitis Vaccine Market Segmentation Analysis

The Global Encephalitis Vaccine Market is segmented on the basis of Strain, End-User, And Geography.

Encephalitis Vaccine Market, By Strain

• Nakayama
• Beijing
• P-3
• SA 14-14-2

Based on Strain, The market is bifurcated into Nakayama, Beijing, P-3, SA 14-14-2. The Nakayama segment accounts for the largest share in the encephalitis vaccine market by strain. It is followed by beijing.

Encephalitis Vaccine Market, By End-User

• Child
• Adult

Based on End-User, The market is bifurcated into Child and Adult. The Encephalitis is seen in children and the adult population. Comparitively, Adult section regisets more number of individuals that are affected each year.

Encephalitis Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Regional Analysis, The Global Encephalitis Vaccine Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America is anticipated to dominate the Encephalitis Vaccine Market and account for the largest share during the forecast period. Rise in investment from the government and public sector and programs to eradicate the disease from the region are the few factors expanding the growth of the market in the North American region. However, the Asia-Pacific market is anticipated to be the fastest-growing market during the forecast period. The prevalence of government-induced immunization programs, growing investment in R&D sector and entry of new vaccine manufacturers in the countries like India and China are majorly possible for the growth of the region.

Key Players

The "Global Encephalitis Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Liaoning Chengda, Valneva, Tiantan Biological Products, Sanofi Pasteur, Chengdu Institute of Biological Products, GlaxoSmithKline plc, Lanzhou Institute of Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, and Biken. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Partnerships, Collaborations and Agreements
• April, 2020 Pfizer Inc. and Valneva SE ("Valneva") announced a collaboration to develop and commercialise Valneva's Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical trials.
• July 2021. GSK and Alector announce a global immuno-neurology collaboration for two clinical-stage first-in-class monoclonal antibodies for neurodegenerative diseases.
• June 23, 2020. Sanofi and Translate Bio are expanding their collaboration to develop mRNA vaccines for all infectious diseases.
• Mergers and Acquisitions
• September 2020 - Sanofi announced that its acquisition of Principia Biopharma Inc. ("Principia") for $100 per share in cash has been completed.
• April 2020. Over a year after the Rs31,700 crore mega-deal was first announced, Hindustan Unilever Ltd (HUL) has completed the merger of GlaxoSmithKline Consumer Healthcare Limited (GSKCH) with itself. HUL will distribute GSK brands such as Eno, Crocin, and Sensodyne in the country under the terms of the agreement.
• Product Launches and Product Expansions
• March 31, 2021. Sanofi will construct a new facility in Canada to increase the global availability of high-dose influenza vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ENCEPHALITIS VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ENCEPHALITIS VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ENCEPHALITIS VACCINE MARKET, BY STRAIN

• 5.1 Overview
• 5.2 Nakayama
• 5.3 Beijing
• 5.4 P-3
• 5.5 SA1414-2

6 GLOBAL ENCEPHALITIS VACCINE MARKET, BY END USER

• 6.1 Overview
• 6.2 Child
• 6.3 Adult

7 GLOBAL ENCEPHALITIS VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL ENCEPHALITIS VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Liaoning Chengda
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Valneva
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Tiantan Biological Products
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Sanofi Pasteur
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Chengdu Institute of Biological Products
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 GlaxoSmithKline plc
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Lanzhou Institute of Biological Products
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Zhejiang Tianyuan Bio-Pharmaceutical
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Biken
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments

10 Appendix

• 10.1 Related Research